ARROWHEAD PHARMACEUTICALS, INC.

ARWR

Explore Our Financial Data > Companies > ARROWHEAD PHARMACEUTICALS, INC.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ARWR
CIK	0000879407
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
Website	arrowheadpharma.com
Phone	626-696-4702
CEO	Christopher R. Anzalone
Employees	400

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$622.01 million
Pre-Tax Income	$-252.26 million
Net Income	$-271.86 million
Net Income to Common	$-300.91 million
EPS	$-2.08

View All

Balance Sheet

Cash	$188.52 million
Assets	$2.27 billion
Liabilities	$1.67 billion
Common Equity	$613.98 million
Liabilities & Equity	$2.27 billion

View All

Cash Flow Statement

Net Income	$-271.86 million
Cash From Operating Activities	$-36.31 million
Cash From Investing Activities	$-704.02 million
Cash From Financing Activities	$741.96 million
Change in Cash	$1.64 million

View All

Calculations

NOPAT	$-155.33 million
EBITDA	$-179.24 million
Price to Earnings	N/A
Price to Book	$18.33
ROE	-42.37%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

PASADENA, Calif., June 22, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). REDEMPLO is the first and only siRNA medicine authorized by the EC for adults with FCS, diagnosed either by the presence of clinical criter

Article Link

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

PASADENA, Calif., June 18, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiM™) platform. Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key o

Article Link

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

Article Link

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

PASADENA, Calif., June 02, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Article Link

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

PASADENA, Calif., May 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study of the Liver Congress (EASL 2026) demonstrate that ARO-INHBE treatment led to clinically meaningful r

Article Link